Investigating the levels of soluble extracellular domain of her2 protein in the sera of meningioma patients

Abtahi, Shabnam; Hakimrabet, Sareh; Malekzadeh, Mahyar; Deghanian, Amir Reza; Ghaderi, Abbas

doi:10.5137/1019-5149.jtn.21536-17.2

Cited by 3 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Abtahi et al demonstrated significantly higher serum levels in grade II meningioma patients compared to grade I (Abtahi et al 2019). However, in addition to the small grade II sample size (n=7) being a limitation of this study, the authors also acknowledge that other studies (Potti et al 2004) have not shown a correlation between high expression of HER2 via IHC and tumour grade or prognosis (Abtahi et al 2019).…”

Section: Blood-based Biomarkersmentioning

confidence: 86%

Biomarkers for differentiating grade II meningiomas from grade I: a systematic review

Sofela

McGavin

Whitfield

et al. 2021

British Journal of Neurosurgery

View full text Add to dashboard Cite

IntroductionThere are a number of prognostic markers (methylation, CDKN2A/B) described to be useful for the stratification of meningiomas. However, there are currently no clinically validated biomarkers for the preoperative prediction of meningioma grade, which is determined by the histological analysis of tissue obtained from surgery.Accurate preoperative biomarkers would inform the pre-surgical assessment of these tumours, their grade and prognosis and refine the decision-making process for treatment. This review is focused on the more controversial grade II tumours, where debate still surrounds the need for adjuvant therapy, repeat surgery and frequency of follow up. MethodsWe evaluated current literature for potential grade II meningioma clinical biomarkers, focusing on radiological, biochemical (blood assays) and immunohistochemical markers for diagnosis and prognosis, and how they can be used to differentiate them from grade I meningiomas using the post-2016 WHO classification. To do this, we conducted a PUBMED, SCOPUS, OVID SP, SciELO, and INFORMA search using the keywords; 'biomarker', 'diagnosis', 'atypical', 'meningioma', 'prognosis', 'grade I', 'grade 1', 'grade II' and 'grade 2'. ResultsWe identified 1779 papers, 20 of which were eligible for systematic review according to the defined inclusion and exclusion criteria. From the review, we identified radiological characteristics (irregular tumour shape, tumour growth rate faster than 3cm 3 /year, high peri-tumoural blood flow), blood markers (low serum TIMP1/2, high serum HER2, high plasma Fibulin-2) and histological markers (low H3K27me3, low SMARCE1, low AKAP12, high ARIDB4) that may aid in differentiating grade II from grade I meningiomas ConclusionBeing able to predict meningioma grade at presentation using the radiological and blood markers described may influence management as the likely grade II tumours will be followed up or treated more aggressively, while the histological markers may prognosticate progression or post-treatment recurrence. This to an extent offers a more personalised treatment approach for patients.

show abstract

Section: Blood-based Biomarkersmentioning

confidence: 86%

Biomarkers for differentiating grade II meningiomas from grade I: a systematic review

Sofela

McGavin

Whitfield

et al. 2021

British Journal of Neurosurgery

View full text Add to dashboard Cite

show abstract

“…Його експресія становить від 2 до 100%. Повідомляють, що Her2 частіше визначається в доброякісних менінгіомах, а саме менінготеліальних та секреторних [17][18][19]. За даними деяких ранніх досліджень, існує обернено пропорційний зв'язок між підвищеною експресією Her2 та ступенем злоякісності пухлини, але інші джерела наявність такого зв'язку спростовують [31].…”

Section: Ukrainian Neurosurgical Journal Vol 29 N2 2023unclassified

“…Менінгіоми іншої локалізації, наприклад, мосто-мозочкового кута, розташування яких щодо внутрішньочерепних структур також значно уск ладнює хірургічне втручання, менш схильні до рецидивування/продовженого росту, ніж менінгіоми ВСС [16]. Деякі автори [17][18][19][20][21][22][23] такий агресивний к лінічний перебіг пояснюють імуногістохімічними та молекулярно-біологічними особливостями менінгіом ВСС.…”

unclassified

“…Her-2/neu (Her2) -тирозинкіназний рецептор сімейства епідермального фактора росту (ERBB2). Його гіперекспресію виявлено у низці злоякісних пухлин людини (аденокарцинома ендометрію, рак молочної залози, шлунка та сечового міхура) [18][19][20]. За даними досліджень, він обернено пропорційно корелює з експресією рецепторів прогестерону та прямо пропорційно -з Кі67 [27].…”

unclassified

See 1 more Smart Citation

The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas

Sirko¹,

Shponka²,

Perepelytsia³

et al. 2023

Ukr Neurosurg J

View full text Add to dashboard Cite

Objective. Determine the role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in predicting the recurrence of parasagittal meningiomas Materials and Methods. The immunohistochemical (IHC) study was conducted in 26 parasagittal meningioma (PM) patients aged 36 to 72, who were treated in the Mechnikov Dnipropetrovsk Regional Clinical Hospital from 2000 to 2021 inclusive. 26 patients were divided into 2 equal groups with the most similar characteristics (patient’s gender, age, and meningioma malignancy as of the time of primary surgery) using the balancing method (pairwise selection). The study group consisted of 13 (50%) patients with detected postoperative PM recurrence/prolonged growth, while the control group included the remaining 13 (50%) patients with no PM recurrence. To evaluate prospects of further studies, the expression of the following markers by the tumor was analyzed: cell proliferation (Ki67), genome stability (p53 protein), dysfunction of epidermal growth factor signaling pathways (ERBB2 or Her-2/neu (Her2)), and cell cycle regulators (cyclin D1 (CyD1)). Results. An association between the PM’s high proliferative activity and its recurrence was moderate (rs=0.44, р=0.025). Median Ki-67 in the study PM group (with recurrence) was three times higher than that in the control group (no recurrence) — 6.0% (4.0%; 9.0%) vs. 2.0% (0.5%; 4.5%) (p=0.029). In the case of Ki67 expression > 4.5%, the risk of PM recurrence/prolonged growth increased by 7.5 times (OR=7.5; 95% CI (1.3–43.0)) (area under the ROC curve, AUC=0.751 (95% CI, 0.544–0.898), p=0.011). The comparative and correlation analysis found no significant association between the p53 protein mutation and the PM recurrence (rs=0.23, р=0.254). Neither we found a significant association between the PM recurrence and the CyD1 expression (rs=0.29, р=0.147) or severity (rs=-0.08, р=0.696). The correlation between the Her2 expression in the PM cells and the PM recurrence was insignificant (rs=0.23, р=0.251). The primary PM malignancy (Grade II–III) increases the risk of unfavorable prognosis by 5.3 times (95% CI, 1.0–29.4) (AUC= 0.722) (95% CI, 0.513–0.878); p=0.016, sensitivity= 61.5%, specificity= 76.9%. Conclusions. The following can be considered probable predictors of the PM recurrence after the primary surgery (within 20 years of follow-up): Ki67 proliferation index > 4.5% and grade II–III tumor malignancy. The comparative and correlation analysis found no statistically significant association between the tumor recurrence and the p53, Her2, and CyD1 immunohistochemical markers. However, the detected significant correlation between the p53, Her2, and CyD1 markers expression and the Ki67 proliferative index and tumor malignancy requires further research with a larger number of clinical observations.

show abstract

“…When active, this receptor binds to dimers, undergoes transphosphorylation and can transduce intracellular signals that may affect cell growth, apoptotic inhibition, migration, invasiveness, and angiogenesis, all of which can lead to tumor progression (41). Its presence is a poor prognostic factor in tumors, particularly breast carcinoma (7,42,43). Studies in the literature on this protein in meningiomas are rare (7,42), and discrepancies between the results are evident (7,40).…”

Section: Introductionmentioning

confidence: 99%

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Carvalho

Silva-Martins

Magalhães³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.

show abstract

Investigating the levels of soluble extracellular domain of her2 protein in the sera of meningioma patients

Cited by 3 publications

References 17 publications

Biomarkers for differentiating grade II meningiomas from grade I: a systematic review

Biomarkers for differentiating grade II meningiomas from grade I: a systematic review

The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Contact Info

Product

Resources

About